Engineering professionals in Pharmaceuticals
Across small molecule, large molecule and combination products, these pharmaceutical engineers hold titles at Merck (two), GSK, Johnson & Johnson Innovative Medicine, AbbVie, Viatris, Baxter International Inc., BeOne Medicines, Catalent Pharma Solutions and SUN PHARMA; three hold global engineering titles. A call fits decisions on API and drug substance scale-up, sterile and injectable facilities, combination device engineering or global capital programs.
Professionals to explore
Ashley Dowling
LinkedInExperience: Senior Director of Engineering Pharma & MedTech · Viatris
Senior Director of Engineering Pharma & MedTech at Viatris since 2022, Ashley Dowling was Engineering Manager - On Body Injector Device MedTech at embecta (2019–2022). Dowling also held Senior Manufacturing Engineer - Engineering Leader MedTech at BD (2017–2019) and process and projects engineering roles at Acelity (2013–2017), and describes 30 years across pharmaceutical, medical device and high-volume manufacturing.
Is this you? Claim your profile and get paid for calls.
Craig J.
LinkedInExperience: VP, Head of Global Engineering · BeOne Medicines
Craig J. has been VP, Head of Global Engineering at BeOne Medicines since 2026 and was SVP, Global Engineering Services at Chobani (2024–2025). Craig J. also held VP, Global Engineering and Facilities at Bristol Myers Squibb (2019–2024), Head of Global Engineering and Maintenance at Sanofi (2016–2019) and Vice President, Global Engineering (formerly Hospira) at Pfizer (2012–2016), the widest global engineering view here.
Is this you? Claim your profile and get paid for calls.
John McGee
LinkedInExperience: Former Engineering Director - Large Molecule Tech Center · Merck
Since 2023, John McGee has been Executive Director - Global Technology Center at Merck, with Engineering Director - Large Molecule Tech Center (2018–2023), Engineering Director - GES MPS Center of Excellence (2013–2018) and Engineering Director - Technology Management Office LSS Lead (2009–2012) roles there. McGee describes over 25 years of process design and capital project engineering and delivery at Merck.
Is this you? Claim your profile and get paid for calls.
Kent Abrahamson
LinkedInExperience: Director of Engineering, Combination Product Development · AbbVie
Kent Abrahamson has been Director of Engineering, Combination Product Development at AbbVie since 2014 and was Director of Product and Site Engineering at Hospira (2007–2014). Abrahamson also held systems and mechanical engineering manager roles for electro-mechanical drug delivery devices at Abbott (2000–2004), which makes Abrahamson a fit for drug-device combination product questions.
Is this you? Claim your profile and get paid for calls.
Kevin O'Keeffe
LinkedInExperience: VP , Head of Engineering Primary & Small Molecule Pharma Manufacturing · GSK
At GSK, Kevin O'Keeffe has been VP , Head of Engineering Primary & Small Molecule Pharma Manufacturing since 2019, with Engineering Head and Acting Site Director, GSK Manufacturing Cork (2013–2018), Head Innovation & Sustainability CoE (2007–2013) and Chemical Engineer (1996–2004) and Lead Project Design Engineer (2005–2007) roles there. O'Keeffe describes 28 years in pharmaceuticals and a technical group delivering sustainability projects.
Is this you? Claim your profile and get paid for calls.
Paul Alexander, P.E.
LinkedInExperience: Former Global Engineering Director · Catalent Pharma Solutions
CAPEX strategy across pharma and biologics is among the areas Paul Alexander, P.E. names. At Catalent Pharma Solutions, Alexander was Global Engineering Director (2012–2016) and has held Sr. Director, Manufacturing Operations & Global Engineering since 2004, and Alexander also held Sr. Engineering and Facilities Manager at Aptuit (2006–2012) and Engineering and Facilities Manager at IQVIA (2004–2006).
Is this you? Claim your profile and get paid for calls.
Richard W. Pranke
LinkedInExperience: Director of Engineering · Merck
Over 30 years in pharmaceutical development and drug substance manufacturing is how Richard W. Pranke describes a career that includes Director of Engineering at Merck since 2026 and Director, Operations Infrastructure Support, Drug Substance Operations and Supply at Bristol Myers Squibb since 2021. At Bristol Myers Squibb, Pranke was also Associate Director, Engineering & Scale-Up Technology, API Operations (2014–2021) and Manager, Process Systems Automation (2010–2014).
Is this you? Claim your profile and get paid for calls.
Robert Wittemann
LinkedInExperience: Director, Large Molecule Drug Product Engineering and Technology · Johnson & Johnson Innovative Medicine
Robert Wittemann has been Director, Large Molecule Drug Product Engineering and Technology at Johnson & Johnson Innovative Medicine since 2023 and was Deputy Director, Global Engineering at Sanofi (2020–2023). At Pfizer, Wittemann was Senior Principal Scientist - Product and Process Technology (2015–2020) and Manager, Process Engineering - Injectable Operations (2004–2015), a fit for large molecule and injectable questions.
Is this you? Claim your profile and get paid for calls.
Vaibhav Mate
LinkedInExperience: Senior Director Baxter Global Engineering · Baxter International Inc.
Aseptic manufacturing and capital management are among the focus areas Vaibhav Mate names as Senior Director Baxter Global Engineering at Baxter International Inc. since 2025, with Director Global Engineering (2022–2025), Sr. Manager Corporate Engineering Baxter Global Operations (2020–2022) and Capital Projects & Engineering Lead Asia Pacific Region (2018–2020) roles there, a fit for capital program questions.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
Small molecule and drug substance questions fit Kevin O'Keeffe and Richard W. Pranke, and large molecule and injectable drug product questions fit Robert Wittemann and John McGee. For global capital programs, Craig J., Vaibhav Mate and Paul Alexander, P.E.; for combination products and devices, Kent Abrahamson and Ashley Dowling; Naveen Kaul covers sterile and oncology facility projects at SUN PHARMA.
Questions to take into the conversation
- 01Which scale-up problems most often appear when an API process moves from development into commercial drug substance manufacturing?
- 02What design choices in a sterile or isolator-based fill line cause the most trouble during qualification?
- 03How do global engineering teams standardize equipment and capital project methods across sites in different regulatory regions?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.